Clinical Trials Logo

Pemphigoid, Bullous clinical trials

View clinical trials related to Pemphigoid, Bullous.

Filter by:

NCT ID: NCT01408550 Completed - Bullous Pemphigoid Clinical Trials

Phase III Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids

Start date: August 2011
Phase: Phase 3
Study type: Interventional

Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days or Placebo(physiological saline). Subsequently, efficacy of NPB-01 for therapy of bullous pemphigoid will be evaluated the score using pemphigus disease area index (PDAI) and pemphigoid activity score involving skin lesion area and Number of new blisters. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by 57 days after the start of the study treatment.

NCT ID: NCT00809822 Completed - Bullous Pemphigoid Clinical Trials

Clinical Trial of NPB-01 in Patients With Bullous Pemphigoid Unresponsive to Corticosteroids.

NPB-01
Start date: November 2008
Phase: Phase 2
Study type: Interventional

Patients diagnosed with bullous pemphigoid were confirmed based on the investigators national diagnostic criteria. Patients who meet all inclusion criteria and conflict the exclusion criteria will receive NPB-01(intravenous immunoglobulin) 400mg/kg/day for five consecutive days or Placebo(physiological saline). Subsequently, efficacy of NPB-01 for therapy of bullous pemphigoid will evaluate using pemphigoid activity score involving skin lesion area and Number of new blisters. As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by 57 days after the start of the study treatment.

NCT ID: NCT00584935 Completed - Clinical trials for Ocular Cicatricial Pemphigoid

Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid

Start date: January 2006
Phase: Phase 1/Phase 2
Study type: Interventional

Cicatricial pemphigoid is an autoimmune blistering disease which affects the skin, mucous membranes, and, in a small subset of patients, the eye. Progressive ocular disease can lead to irreversible damage and blindness. Conventional treatments include systemic steroids, dapsone, and immunosuppressive agents. These treatments, however, are not successful with all patients. Rituximab has been very effective in the treatment of other autoimmune disorders, and has recently been shown to be effective for autoimmune blistering pemphigus. We propose that it will also be effective in the treatment of cicatricial pemphigoid.

NCT ID: NCT00525616 Completed - Bullous Pemphigoid Clinical Trials

Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

Rituximab2
Start date: December 2008
Phase: Phase 3
Study type: Interventional

The aim of the study is to assess that it will be possible to control with a single cycle of rituximab patient with bullous pemphigoid.

NCT ID: NCT00472030 Completed - Bullous Pemphigoid Clinical Trials

Efficacy and Safety of Omalizumab in Bullous Pemphigoid

Start date: August 2007
Phase: Phase 4
Study type: Interventional

The primary objective is to test the safety and efficacy of Xolair in the treatment of the autoimmune blistering disease, bullous pemphigoid (BP). This is a pilot, open label case-control study. Patients treated with Xolair will be compared to patients receiving standard treatment with prednisone. The enrollment period for the study is 24 weeks: 16 weeks active treatment and 8 additional weeks of observation.

NCT ID: NCT00431119 Completed - Bullous Pemphigoid Clinical Trials

Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid

Start date: October 1997
Phase: Phase 2
Study type: Interventional

To investigate the safety and efficacy of oral methylprednisolone combined with azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.

NCT ID: NCT00286325 Completed - Bullous Pemphigoid Clinical Trials

Rituximab in the Treatment of Patients With Bullous Pemphigoid

Start date: March 2005
Phase: Phase 1/Phase 2
Study type: Interventional

This study will determine the safety of treatment of bullous pemphigoid in patients resistant to therapy with systemic corticosteroids, with rituximab plus systemic corticosteroids.

NCT ID: NCT00213421 Completed - Bullous Pemphigoid Clinical Trials

Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus

Start date: August 2001
Phase: Phase 4
Study type: Observational

to compare efficacity and tolerance of two stratégies of dermoval application in treatment of bullous pemphigus.